Galera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Galera Therapeutics's estimated annual revenue is currently $6.8M per year.
- Galera Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Galera Therapeutics has 34 Employees.
- Galera Therapeutics grew their employee count by -32% last year.
Galera Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Regulatory and Quality Officer | Reveal Email/Phone |
3 | Co-Founder, Executive Chair & Chief Operating Officer | Reveal Email/Phone |
4 | CSO | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | SVP, Regulatory Affairs | Reveal Email/Phone |
7 | VP Commercial Operations | Reveal Email/Phone |
8 | VP Market Access | Reveal Email/Phone |
9 | SVP, Clinical Operations and Data Management | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
Galera Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.6M | 232 | 8% | N/A | N/A |
#2 | $84.2M | 419 | 3% | N/A | N/A |
#3 | $14.1M | 70 | 0% | N/A | N/A |
#4 | $1224.3M | 6091 | -9% | N/A | N/A |
#5 | $43.2M | 215 | -4% | N/A | N/A |
#6 | $12.3M | 61 | -6% | N/A | N/A |
#7 | $19.9M | 99 | 41% | N/A | N/A |
#8 | $16.5M | 82 | -5% | N/A | N/A |
#9 | $97.7M | 486 | 30% | N/A | N/A |
#10 | $12.5M | 62 | -16% | N/A | N/A |
What Is Galera Therapeutics?
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
keywords:N/A
N/A
Total Funding
34
Number of Employees
$6.8M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Galera Therapeutics News
2022-04-20 - Galera to Present at 2022 American Society of Clinical ...
MALVERN, PA Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe...
2022-04-13 - Financial Survey: Galera Therapeutics (NASDAQ:GRTX ...
Financial Survey: Galera Therapeutics (NASDAQ:GRTX) versus Prestige Consumer Healthcare (NYSE:PBH). Posted by admin on Apr 22nd, 2022.
2022-04-06 - Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 ...
Galera Therapeutics, Inc. (NASDAQ:GRTX) Receives $12.45 Consensus PT from Analysts. Posted by admin on Apr 17th, 2022.
Other Companies in Malvern
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 35 | 3% | N/A |
#2 | $9.9M | 35 | 6% | N/A |
#3 | $6M | 36 | -3% | N/A |
#4 | $6.7M | 38 | -3% | N/A |
#5 | $8.8M | 38 | 36% | N/A |